Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.63 and traded as low as $0.31. Vaxart shares last traded at $0.32, with a volume of 1,136,429 shares traded.

Analyst Upgrades and Downgrades

Separately, B. Riley reduced their price objective on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Thursday, March 27th.

Vaxart Stock Up 11.3 %

The business has a 50 day moving average price of $0.45 and a two-hundred day moving average price of $0.62. The stock has a market cap of $91.44 million, a P/E ratio of -0.98 and a beta of 1.57.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.19 million during the quarter, compared to the consensus estimate of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. On average, research analysts forecast that Vaxart, Inc. will post -0.39 earnings per share for the current year.

Hedge Funds Weigh In On Vaxart

Several institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 17,942 shares during the last quarter. Invesco Ltd. boosted its stake in Vaxart by 48.6% during the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after buying an additional 24,803 shares during the last quarter. Graham Capital Management L.P. boosted its stake in Vaxart by 155.8% during the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after buying an additional 32,482 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after buying an additional 35,213 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Vaxart by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after acquiring an additional 57,911 shares during the last quarter. 18.05% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.